echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: The effect of behavioral intervention for weight loss and metformin on insulin-like growth factors in cancer survivors

    JCEM: The effect of behavioral intervention for weight loss and metformin on insulin-like growth factors in cancer survivors

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Elevated levels of insulin-like growth factor-1 (IGF-1) are associated with increased cancer risk and mortality.
    Lowering the level of IGF-1 is
    a promising treatment to
    prevent its recurrence.

    prevention

    Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
    This randomized, three-group parallel controlled clinical trial included overweight or obese cancer survivors and randomized them Assigned to 1) self-controlled weight loss group (control group), 2) coach-guided weight loss group or 3)
    metformin treatment group.
    The main outcome of the study was the changes in IGF-1 levels and IGF-1:IGFBP3 molar ratio at six months.
    The duration of the test is 12 months.

    Metformin

    Among 121 random participants, 79% were women, 46% were African Americans, and the average age was 60 years.
    At baseline, the subjects’ average BMI was 35 kg/m 2; the average level of IGF-1 was 72.
    9 (SD: 21.
    7) ng/ml; the average molar ratio of IGF1:IGFBP3 was 0.
    17 (SD: 0.
    05).
    At 6 months, the weight changes of subjects in the self-directed group, coach-directed group, and metformin treatment group were -1.
    0% (p=0.
    07), -4.
    2% (p<0.
    0001), and -2.
    8% (p<0.
    0001), respectively ).

    Compared with the self-directed group, at 3 months, participants in the metformin treatment group had IGF-1 levels (mean change: -5.
    50 ng/ml, p=0.
    02) and IGF1:IGFBP3 molar ratio (mean change: -0.
    0119, p=0.
    011) Significantly reduced.
    Obese subjects still significantly reduced IGF-1 levels at 6 months (mean difference in change: -7.
    2 ng/ml; 95% CI: -13.
    3 to -1.
    1), while overweight subjects did not (interaction p=0.
    045).
    There was no significant difference in weight change between the coaching group and the self-directing group.
    At 12 months, there was no difference in the outcome of the study.

    This shows that among obese cancer survivors, metformin may have a short-term effect on the reduction of IGF-1, but it will gradually disappear over time .

    Among obese cancer survivors, metformin may have a short-term effect on the reduction of IGF-1, but it will gradually disappear over time

    Original source:

    Original source:

    Hsin-Chieh Yeh.
    et al.
    org/10.
    1210/clinem/dgab266" target="_blank" rel="noopener">Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial .
    JCEM.
    2021.
    https://doi.
    org/10.
    1210/clinem/dgab266

    org/10.
    1210/clinem/dgab266" target="_blank" rel="noopener">Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.